Journal of Clinical Oncology, Vol 16, 2921-2929, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients

U Keilholz, C Conradt, SS Legha, D Khayat, C Scheibenbogen, N Thatcher, SH Goey, M Gore, T Dorval, B Hancock, CJ Punt, R Dummer, MF Avril, EB Brocker, A Benhammouda, AM Eggermont and M Pritsch
Department of Medicine III (Hematology/Oncology/Transfusion Medicine), University Hospital Benjamin Franklin, Free University Berlin, Germany. Keilholz@ukbf.fu-berlin.de

PURPOSE: In patients with stage IV melanoma, durable responses have been reported with treatment regimens that involve high-dose interleukin-2 (IL-2). We analyze long-term results of 631 melanoma patients from 12 institutions who had received IL-2 alone, in combination with interferon alfa 2a or 2b (IFNalpha), or with cytotoxic drugs. METHODS: Case records that contained pretreatment parameters, response data, and updated survival information were collected. After univariate analysis, the multivariate evaluation of the impact of pretreatment parameters on response and survival was performed by logistic regression and Cox's regression, respectively. RESULTS: Patients were divided into four groups according to treatment: IL-2 alone (n=117), IL-2 and chemotherapy (n=49), IL-2 and IFNalpha (n=153), and IL-2, chemotherapy, and IFNalpha (n=312). The median survival of all patients was 10.5 months and the 2- and 5-year survival rates were 19.9% and 10.4%, respectively. Independent prognostic factors for response and survival were entirely different, treatment group being the only significant factor for response, and serum lactate dehydrogenase (LDH), metastatic site, and performance predicting survival. The addition of IFNalpha to IL-2 was associated with prolonged survival, but the effect of additional chemotherapy was less obvious. CONCLUSION: Serum LDH, metastatic site, and performance status are useful stratification factors for randomized trials in metastatic melanoma. The improved long-term survival rates observed in melanoma patients treated with IL-2/IFNalpha-containing regimens are notable in contrast to the reported 5-year survival rates of 2% to 6% achieved with chemotherapy, but because selection bias cannot be ruled out, the impact of IL-2, as well as all other components of the treatment regimens, on survival needs to be confirmed in prospective randomized trials.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. J. O'Day, M. B. Atkins, P. Boasberg, H.-J. Wang, J. A. Thompson, C. M. Anderson, R. Gonzalez, J. Lutzky, T. Amatruda, E. M. Hersh, et al. Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma J. Clin. Oncol., December 20, 2009; 27(36): 6207 - 6212. [Abstract] [Full Text] [PDF]

				D. Schadendorf, S. M. Algarra, L. Bastholt, G. Cinat, B. Dreno, A. M. M. Eggermont, E. Espinosa, J. Guo, A. Hauschild, T. Petrella, et al. Immunotherapy of distant metastatic disease Ann. Onc., August 1, 2009; 20(suppl_6): vi41 - vi50. [Abstract] [Full Text] [PDF]

				A. A. Tarhini, J. Stuckert, S. Lee, C. Sander, and J. M. Kirkwood Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694 J. Clin. Oncol., January 1, 2009; 27(1): 38 - 44. [Abstract] [Full Text] [PDF]

				M. B. Atkins, J. Hsu, S. Lee, G. I. Cohen, L. E. Flaherty, J. A. Sosman, V. K. Sondak, and J. M. Kirkwood Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group J. Clin. Oncol., December 10, 2008; 26(35): 5748 - 5754. [Abstract] [Full Text] [PDF]

				D. F. McDermott, J. A. Sosman, R. Gonzalez, F. S. Hodi, G. P. Linette, J. Richards, J. W. Jakub, M. Beeram, S. Tarantolo, S. Agarwala, et al. Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group J. Clin. Oncol., May 1, 2008; 26(13): 2178 - 2185. [Abstract] [Full Text] [PDF]

				E. L. Korn, P.-Y. Liu, S. J. Lee, J.-A. W. Chapman, D. Niedzwiecki, V. J. Suman, J. Moon, V. K. Sondak, M. B. Atkins, E. A. Eisenhauer, et al. Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials J. Clin. Oncol., February 1, 2008; 26(4): 527 - 534. [Abstract] [Full Text] [PDF]

				N. J. Ives, R. L. Stowe, P. Lorigan, and K. Wheatley Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients J. Clin. Oncol., December 1, 2007; 25(34): 5426 - 5434. [Abstract] [Full Text] [PDF]

				H. Schmidt, S. Suciu, C. J.A. Punt, M. Gore, W. Kruit, P. Patel, D. Lienard, H. von der Maase, A. M.M. Eggermont, and U. Keilholz Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial J. Clin. Oncol., April 20, 2007; 25(12): 1562 - 1569. [Abstract] [Full Text] [PDF]

				A. M.M. Eggermont Reaching First Base in the Treatment of Metastatic Melanoma J. Clin. Oncol., October 10, 2006; 24(29): 4673 - 4674. [Full Text] [PDF]

				E. M. Noorda, B. C. Vrouenraets, O. E. Nieweg, B. N. van Geel, A. M. M. Eggermont, and B. B. R. Kroon Isolated Limb Perfusion for Unresectable Melanoma of the Extremities Arch Surg, November 1, 2004; 139(11): 1237 - 1242. [Abstract] [Full Text] [PDF]

				H. Tsao, M. B. Atkins, and A. J. Sober Management of Cutaneous Melanoma N. Engl. J. Med., September 2, 2004; 351(10): 998 - 1012. [Full Text] [PDF]

				C. M. Balch, S.-J. Soong, M. B. Atkins, A. C. Buzaid, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr., J. M. Kirkwood, et al. An Evidence-based Staging System for Cutaneous Melanoma CA Cancer J Clin, May 1, 2004; 54(3): 131 - 149. [Abstract] [Full Text] [PDF]

				A. Hauschild, M. Weichenthal, B.-R. Balda, J. C. Becker, H. H. Wolff, W. Tilgen, K.-W. Schulte, J. Ring, D. Schadendorf, S. Lischner, et al. Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node Metastasis J. Clin. Oncol., August 1, 2003; 21(15): 2883 - 2888. [Abstract] [Full Text] [PDF]

				M. B. Atkins, J. A. Gollob, J. A. Sosman, D. F. McDermott, L. Tutin, P. Sorokin, R. A. Parker, and J. W. Mier A Phase II Pilot Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Temozolomide, Interleukin 2, and IFN-{alpha}2B in Patients with Metastatic Melanoma Clin. Cancer Res., October 1, 2002; 8(10): 3075 - 3081. [Abstract] [Full Text] [PDF]

				S. J. O'Day, P. D. Boasberg, L. Piro, T. S. Kristedja, H.-J. Wang, M. Martin, R. Deck, P. Ames, K. Shinn, H. Kim, et al. Maintenance Biotherapy for Metastatic Melanoma with Interleukin-2 and Granulocyte Macrophage-Colony Stimulating Factor Improves Survival for Patients Responding to Induction Concurrent Biochemotherapy Clin. Cancer Res., September 1, 2002; 8(9): 2775 - 2781. [Abstract] [Full Text] [PDF]

				J. Koduri, M. A. Baumann, R. Ridolfi, and O. Nanni Cisplatin and Dacarbazine With or Without Subcutaneous Interleukin-2 and Interferon Alfa-2b in Advanced Melanoma Outpatients J. Clin. Oncol., August 15, 2002; 20(16): 3560 - 3561. [Full Text] [PDF]

				R. Ridolfi, V. Chiarion-Sileni, M. Guida, A. Romanini, R. Labianca, A. Freschi, G. Lo Re, R. Nortilli, S. Brugnara, P. Vitali, et al. Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial J. Clin. Oncol., March 15, 2002; 20(6): 1600 - 1607. [Abstract] [Full Text] [PDF]

				C. M. Balch and M. C. Mihm Reply to the article "The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group", by D. J. Ruiter et al. (Ann Oncol 2001; 12: 9-11) Ann. Onc., January 19, 2002; 13(1): 175 - 176. [Full Text] [PDF]

				S. S. Agarwala, J. Glaspy, S. J. O'Day, M. Mitchell, J. Gutheil, E. Whitman, R. Gonzalez, E. Hersh, L. Feun, R. Belt, et al. Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma J. Clin. Oncol., January 1, 2002; 20(1): 125 - 133. [Abstract] [Full Text] [PDF]

				A. C. Buzaid and M. Atkins Practical Guidelines for the Management of Biochemotherapy-related Toxicity in Melanoma Clin. Cancer Res., September 1, 2001; 7(9): 2611 - 2619. [Abstract] [Full Text] [PDF]

				C. M. Balch, S.-J. Soong, J. E. Gershenwald, J. F. Thompson, D. S. Reintgen, N. Cascinelli, M. Urist, K. M. McMasters, M. I. Ross, J. M. Kirkwood, et al. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System J. Clin. Oncol., August 15, 2001; 19(16): 3622 - 3634. [Abstract] [Full Text] [PDF]

				C. M. Balch, A. C. Buzaid, S.-J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr, J. M. Kirkwood, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma J. Clin. Oncol., August 15, 2001; 19(16): 3635 - 3648. [Abstract] [Full Text] [PDF]

				T. M. Carlos Leukocyte recruitment at sites of tumor: dissonant orchestration J. Leukoc. Biol., August 1, 2001; 70(2): 171 - 184. [Abstract] [Full Text] [PDF]

				L. E. Flaherty, M. Atkins, J. Sosman, G. Weiss, J. I. Clark, K. Margolin, J. Dutcher, M. S. Gordon, M. Lotze, J. Mier, et al. Outpatient Biochemotherapy With Interleukin-2 and Interferon Alfa-2b in Patients With Metastatic Malignant Melanoma: Results of Two Phase II Cytokine Working Group Trials J. Clin. Oncol., July 1, 2001; 19(13): 3194 - 3202. [Abstract] [Full Text] [PDF]

				F. Recchia, S. De Filippis, M. Rosselli, G. Saggio, A. Cesta, L. Fumagalli, and S. Rea Phase 1B Study of Subcutaneously Administered Interleukin 2 in Combination with 13-cis Retinoic Acid as Maintenance Therapy in Advanced Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1251 - 1257. [Abstract] [Full Text]

				J. Manola, M. Atkins, J. Ibrahim, and J. Kirkwood Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials J. Clin. Oncol., November 15, 2000; 18(22): 3782 - 3793. [Abstract] [Full Text] [PDF]

				P. J. Delves and I. M. Roitt The Immune System- First of Two Parts N. Engl. J. Med., July 6, 2000; 343(1): 37 - 49. [Full Text] [PDF]

				G. C. de Gast, H.-J. Klumpen, F. A. Vyth-Dreese, M.-J. Kersten, N. C. V. Verra, J. Sein, D. Batchelor, W. J. Nooijen, and J. H. Schornagel Phase I Trial of Combined Immunotherapy with Subcutaneous Granulocyte Macrophage Colony-stimulating Factor, Low-Dose Interleukin 2, and Interferon {{alpha}} in Progressive Metastatic Melanoma and Renal Cell Carcinoma Clin. Cancer Res., April 1, 2000; 6(4): 1267 - 1272. [Abstract] [Full Text]

				K. A. Foon, J. Lutzky, R. N. Baral, J. R. Yannelli, L. Hutchins, A. Teitelbaum, O. L. Kashala, R. Das, J. Garrison, R. A. Reisfeld, et al. Clinical and Immune Responses in Advanced Melanoma Patients Immunized With an Anti-Idiotype Antibody Mimicking Disialoganglioside GD2 J. Clin. Oncol., January 14, 2000; 18(2): 376 - 376. [Abstract] [Full Text] [PDF]

				S. J. O'Day, G. Gammon, P. D. Boasberg, M. A. Martin, T. S. Kristedja, M. Guo, S. Stern, S. Edwards, P. Fournier, M. Weisberg, et al. Advantages of Concurrent Biochemotherapy Modified by Decrescendo Interleukin-2, Granulocyte Colony-Stimulating Factor, and Tamoxifen for Patients With Metastatic Melanoma J. Clin. Oncol., September 1, 1999; 17(9): 2752 - 2752. [Abstract] [Full Text] [PDF]